Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells

Nature ◽  
1984 ◽  
Vol 307 (5953) ◽  
pp. 745-747 ◽  
Author(s):  
W. J. King ◽  
G. L. Greene
Keyword(s):  
Monoclonal Antibodies ◽  
Oestrogen Receptor ◽  
Target Cells

scholarly journals Antibody-based therapy of leukaemia

2009 ◽  
Vol 11 ◽  
Author(s):  
John C. Morris ◽  
Thomas A. Waldmann
Keyword(s):  
Monoclonal Antibodies ◽  
T Cell ◽  
B Cell ◽  
Gemtuzumab Ozogamicin ◽  
Cell Leukaemia ◽  
Target Cells ◽  
Immune Effector ◽  
Effector Cells ◽  
Prolymphocytic Leukaemia ◽  
Immune Effector Cells

Over the past decade, monoclonal antibodies have dramatically impacted the treatment of haematological malignancies, as evidenced by the effect of rituximab on the response rate and survival of patients with follicular and diffuse large B cell non-Hodgkin's lymphoma. Currently, only two monoclonal antibodies – the anti-CD33 immunotoxin gemtuzumab ozogamicin and the CD52-directed antibody alemtuzumab – are approved for treatment of relapsed acute myeloid leukaemia in older patients and B cell chronic lymphocytic leukaemia, respectively. Although not approved for such treatment, alemtuzumab is also active against T cell prolymphocytic leukaemia, cutaneous T cell lymphoma and Sézary syndrome, and adult T cell leukaemia and lymphoma. In addition, rituximab has demonstrated activity against B cell chronic lymphocytic and hairy cell leukaemia. Monoclonal antibodies targeting CD4, CD19, CD20, CD22, CD23, CD25, CD45, CD66 and CD122 are now being studied in the clinic for the treatment of leukaemia. Here, we discuss how these new antibodies have been engineered to reduce immunogenicity and improve antibody targeting and binding. Improved interactions with Fc receptors on immune effector cells can enhance destruction of target cells through antibody-dependent cellular cytotoxicity and complement-mediated cell lysis. The antibodies can also be armed with cellular toxins or radionuclides to enhance the destruction of leukaemia cells.

Side-Effects of Monoclonal Antibody Infusions for the Diagnosis and Treatment of Cancer

1988 ◽  
Vol 3 (3) ◽  
pp. 147-153 ◽  
Author(s):  
E.F.H. van der Linden ◽  
M.J.P.G. van Kroonenburgh ◽  
E.K.J. Pauwels
Keyword(s):  
Monoclonal Antibody ◽  
Monoclonal Antibodies ◽  
Side Effects ◽  
Diagnosis And Treatment ◽  
Target Cells ◽  
Clinical Use ◽  
Skin Reactions ◽  
Discontinuation Of Treatment ◽  
Diagnostic Applications ◽  
Toxic Reactions

This literature review presents an inventory of the nature and incidence of side-effects that arise from the clinical application of monoclonal antibodies (MoAb) for the diagnosis and treatment of cancer. Most side-effects occurred during therapy. Toxic reactions, such as fever, sweating and chills, were more common than immunological skin reactions; they were observed predominantly in association with the elimination of circulating target cells. Dosage and rate of administration of the MoAb appeared to have little influence on the reactions, which disappeared quickly and did not necessitate discontinuation of treatment. Serum sickness, anaphylactic reactions and bronchospasms were not common; the patients reacted quickly to the indicated therapy. Prevention of the side-effects described here, especially during diagnostic applications, was such that they need not form a barrier to the clinical use of MoAb.

AN IMPORTANT ROLE OF CARBOHYDRATE MOIETIES ON CANCER CELL MEMBRANE GLYCOPROTEINS IN CANCER CELL-INDUCED PLATELET AGGREGATION

1987 ◽  
Author(s):  
H Kitagawa ◽  
N Yamamoto ◽  
G Kosaki ◽  
H Yamazaki
Keyword(s):  
Monoclonal Antibodies ◽  
Platelet Aggregation ◽  
Cell Membrane ◽  
Western Blot ◽  
Cancer Cells ◽  
Cell Line ◽  
Cancer Cell ◽  
Target Cells ◽  
Membrane Glycoproteins ◽  
Induced Aggregation

Platelet aggregation induced by cancer cells may be an essential process in the development of hematogenous metastasis of cancers. A mechanism in HMV-I (human vaginal melanoma cell line)-induced platelet aggregation was studied by using monoclonal antibodies against membrane proteins of cancer cells or platelets. HMV-I cells or their membrana ractions induced platelet aggregation of human heparinized PRP, to which hirudin had no inhibitory effect. The platelet aggregation by HMV-I was completely lost after the pretreatment of the cells with 0.3U/ml neuraminidase for 60 min at 37°C. Preincubation of platelets with monoclonal antibodies against platelet GP lb or GP Ilb/lIIa inhibited HMV-I induced aggregation. A monoclonal antibody MB3 (igM) against another human melanoma (HMMB) which had been transplanted in nude mice was produced by hybridoma technique. Screening studies by cell binding ELISA revealed that MB3 antibody reacted with not only HMMB cells but also many other cells including HMV-I, M7609 (colon carcinoma cell line) and normal fibroblasts. Western-blot analyses showedthat MB3 antibody reacted with multiple, more than ten, proteins with molecular weights ranging from UO to 200 kDa in unreduced SDS-PAGE of HMV-I, HMMB or M7609. In contrast, when .these cells pretreated with neuraminidase were used in Western-blot, MB3 reactivity were all lost. MB3 reacted with at least three glycoproteins of human red cell membrane in Western-blot, but it did not react with human platelets. Immune adherent asgay with trypsin-treated HMV-I or HMMB cells as target cells showed negative reactivity. MB3 antibody inhibited HMV-I-induced aggregation of platelets, but did not inhibit M7609-induced aggregation which depended on thrombin generation.These results suggest that MB3 antibody may be against sialic acid-containing carbohydrate moieties of membrane glycoproteins on these cancercells and that the carbohydrate(s) may play a critical role in' cancer cell-platelet interaction.

Costimulatory Effects of Interleukin-18 (IL-18) on Human Natural Killer (NK) Cells Activated through Fc Receptors for Immunoglobulin (IgG)

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 2780-2780
Author(s):  
Shivani Srivastava ◽  
Hailin Feng ◽  
Menggang Yu ◽  
David Pelloso ◽  
Michael Robertson
Keyword(s):  
Monoclonal Antibodies ◽  
Nk Cells ◽  
Cell Function ◽  
Nk Cell ◽  
Conflicts Of Interest ◽  
Fc Receptors ◽  
Cytolytic Activity ◽  
Mitogen Activated Protein Kinase ◽  
Target Cells

Abstract Abstract 2780 NK cells play an important role in innate and adaptive immune responses. Most human NK cells express CD16, an Fc receptor for IgG that mediates lysis of antibody-coated target cells and costimulates interferon (IFN)-g production in response to cytokines. IL-18 is an immunostimulatory cytokine with antitumor activity in preclinical animal models. The effects of IL-18 on human NK cell function were examined. Here we show that NK cells stimulated with immobilized IgG in vitro secreted IFN-g; such IFN-g production was partially inhibited by blocking CD16 with monoclonal antibodies. IL-18 augmented IFN-g production by NK cells stimulated with immobilized IgG or CD16 antibodies (Figure 1). NK cell IFN-g production in response to immobilized IgG and/or IL-18 was inhibited by chemical inhibitors of Syk, extracellular signal-related kinases (ERK), p38 mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3-kinase (PI3-K). Stimulation with IL-18 or immobilized IgG could augment IL-12-induced IFN-g production by STAT4-deficient lymphocytes obtained from lymphoma patients after autologous stem cell transplantation (Figure 2). IL-18 also augmented the in vitro lysis of rituximab-coated Raji cells by human NK cells (Figure 3). These observations that IL-18 can co stimulate IFN-g production and cytolytic activity of NK cells activated through Fc receptors makes it an attractive cytokine to combine with monoclonal antibodies for treatment of cancer. Disclosure: No relevant conflicts of interest to declare.

Immunotoxins containing saporin 6 and monoclonal antibodies recognizing plasma cell-associated antigens: Effects on target cells and on normal myeloid precursors (CFU-GM)

2009 ◽  
Vol 42 (3) ◽  
pp. 238-245 ◽  
Author(s):  
Luigi Barbieri ◽  
Angelo Dinota ◽  
Marco Gobbi ◽  
Pier Luigi Tazzari ◽  
Simonetta Rizzi ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Plasma Cell ◽  
Target Cells

scholarly journals Different D end-dependent antigenic determinants are recognized by H-2-restricted cytotoxic T cells specific for influenza and Bebaru viruses.

1979 ◽  
Vol 150 (1) ◽  
pp. 166-163 ◽  
Author(s):  
R V Blanden ◽  
A Müllbacher ◽  
R B Ashman
Keyword(s):  
T Cells ◽  
Monoclonal Antibodies ◽  
Cytotoxic T Cells ◽  
Influenza Viruses ◽  
The Other ◽  
Antigenic Determinants ◽  
Target Cells ◽  
Specific Lysis

Two different BALB/c anti-CBA (H-2k)monoclonal antibodies that bind to Kk and Dk antigens blocked Tc cell-mediated lysis of L929 (Kk, Dk) target cells, but with quite different specificity. One antibody (30R3) powerfully blocked Kk-specific lysis mediated by alloreactive or Kk-restricted Tc cells immune to ectromelia, Sendai, or influenza viruses. The other antibody (27R9) blocked these anti-Kk Tc cells much less than 30R3, but in contrast, 27R9 blocked anti-Dk lysis much more than 30R3. Most importantly, 27R9 strongly blocked Dk-restricted anti-influenza Tc cells, but did not significantly block Dk-restricted anti-Bebaru (BEB) lysis. This result indicated that different H-2 determinants coded in the D end of H-2k were recognized by influenza-and BEB-immune Tc cells. These determinants may be carried on two different molecules coded by the H-2D and H-2L loci, but other possibilities are not yet excluded.

scholarly journals Functional Evaluation of DC-SIGN Monoclonal Antibodies Reveals DC-SIGN Interactions with ICAM-3 Do Not Promote Human Immunodeficiency Virus Type 1 Transmission

2002 ◽  
Vol 76 (12) ◽  
pp. 5905-5914 ◽  
Author(s):  
Li Wu ◽  
Thomas D. Martin ◽  
Rosemay Vazeux ◽  
Derya Unutmaz ◽  
Vineet N. KewalRamani
Keyword(s):  
T Cells ◽  
Monoclonal Antibodies ◽  
Virus Transmission ◽  
Interleukin 4 ◽  
Intercellular Adhesion Molecule ◽  
Target Cells ◽  
Functional Evaluation ◽  
Immunodeficiency Virus ◽  
Hiv 1

ABSTRACT DC-SIGN, a type II membrane-spanning C-type lectin that is expressed on the surface of dendritic cells (DC), captures and promotes human and simian immunodeficiency virus (HIV and SIV) infection of CD4+ T cells in trans. To better understand the mechanism of DC-SIGN-mediated virus transmission, we generated and functionally evaluated a panel of seven monoclonal antibodies (MAbs) against DC-SIGN family molecules. Six of the MAbs reacted with myeloid-lineage DC, whereas one MAb preferentially bound DC-SIGNR/L-SIGN, a homolog of DC-SIGN. Characterization of hematopoietic cells also revealed that stimulation of monocytes with interleukin-4 (IL-4) or IL-13 was sufficient to induce expression of DC-SIGN. All DC-SIGN-reactive MAbs competed with intercellular adhesion molecule 3 (ICAM-3) for adhesion to DC-SIGN and blocked HIV-1 transmission to T cells that was mediated by THP-1 cells expressing DC-SIGN. Similar but less efficient MAb blocking of DC-mediated HIV-1 transmission was observed, indicating that HIV-1 transmission to target cells via DC may not be dependent solely on DC-SIGN. Attempts to neutralize DC-SIGN capture and transmission of HIV-1 with soluble ICAM-3 prophylaxis were limited in success, with a maximal inhibition of 60%. In addition, disrupting DC-SIGN/ICAM-3 interactions between cells with MAbs did not impair DC-SIGN-mediated HIV-1 transmission. Finally, forced expression of ICAM-3 on target cells did not increase their susceptibility to HIV-1 transmission mediated by DC-SIGN. While these findings do not discount the role of intercellular contact in facilitating HIV-1 transmission, our in vitro data indicate that DC-SIGN interactions with ICAM-3 do not promote DC-SIGN-mediated virus transmission.

scholarly journals The Adenylate Cyclase Toxin of Bordetella pertussis Binds to Target Cells via the αMβ2 Integrin (Cd11b/Cd18)

2001 ◽  
Vol 193 (9) ◽  
pp. 1035-1044 ◽  
Author(s):  
Pierre Guermonprez ◽  
Nadia Khelef ◽  
Eric Blouin ◽  
Philippe Rieu ◽  
Paola Ricciardi-Castagnoli ◽  
...  
Keyword(s):  
Cell Death ◽  
Monoclonal Antibodies ◽  
Adenylate Cyclase ◽  
Cell Lines ◽  
Bordetella Pertussis ◽  
Chinese Hamster Ovary Cells ◽  
Human Neutrophils ◽  
Target Cells ◽  
Intracellular Camp ◽  
Adenylate Cyclase Toxin

The adenylate cyclase toxin (CyaA) of Bordetella pertussis is a major virulence factor required for the early phases of lung colonization. It can invade eukaryotic cells where, upon activation by endogenous calmodulin, it catalyzes the formation of unregulated cAMP levels. CyaA intoxication leads to evident toxic effects on macrophages and neutrophils. Here, we demonstrate that CyaA uses the αMβ2 integrin (CD11b/CD18) as a cell receptor. Indeed, the saturable binding of CyaA to the surface of various hematopoietic cell lines correlated with the presence of the αMβ2 integrin on these cells. Moreover, binding of CyaA to various murine cell lines and human neutrophils was specifically blocked by anti-CD11b monoclonal antibodies. The increase of intracellular cAMP level and cell death triggered by CyaA intoxication was also specifically blocked by anti-CD11b monoclonal antibodies. In addition, CyaA bound efficiently and triggered intracellular cAMP increase and cell death in Chinese hamster ovary cells transfected with αMβ2 (CD11b/CD18) but not in cells transfected with the vector alone or with the αXβ2 (CD11c/CD18) integrin. Thus, the cellular distribution of CD11b, mostly on neutrophils, macrophages, and dendritic and natural killer cells, supports a role for CyaA in disrupting the early, innate antibacterial immune response.

Sign in / Sign up

Export Citation Format

Share Document